ArticleBMJ case reports2025
Sustained remission with eculizumab in refractory lupus nephritis with atypical haemolytic uraemic syndrome.
Article in BMJ case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Complement-amplified thrombotic microangiopathy in systemic lupus erythematosus and lupus nephritis: a systematic review of 78 reported patients.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus with approximately 50% of patients having renal involvement. Patients who fail to respond to appropriate induction immunosuppression are considered to have refractory disease. Refractory LN is associated with increased risk of progression to end-stage chronic kidney disease and mortality. Despite the development of modern therapeutics, refractory LN remains challenging in clinical practice and continues to be associated with treatment failure. Complement has a well-described role in the pathogenesis of LN; however, complement inhibition is not routinely used for refractory disease. We present the case of a woman in her 30s with refractory LN who presented with atypical haemolytic uraemic syndrome, macrophage activation syndrome and low-severity COVID-19 infection. She was treated with eculizumab with rapid clinical and biochemical improvement. The patient achieved complete remission of her refractory LN after eculizumab and remains in remission 2 years post eculizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.